company background image
FRE logo

Fresenius SE KGaA Informe acción XTRA:FRE

Último precio

€33.31

Capitalización de mercado

€18.8b

7D

-0.1%

1Y

19.2%

Actualizada

24 Nov, 2024

Datos

Finanzas de la empresa +

Fresenius SE & Co. KGaA

Informe acción XTRA:FRE

Capitalización de mercado: €18.8b

Resumen de acción FRE

Fresenius SE & Co. KGaA, una empresa de asistencia sanitaria, ofrece productos y servicios para pacientes con enfermedades crónicas. Saber más

Análisis fundamental de FRE
Puntuación del snowflake
Valoración5/6
Crecimiento futuro3/6
Rendimiento pasado0/6
Salud financiera4/6
Dividendos0/6

Recompensas

Cotiza un 62.9% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 38.96%

Los analistas coinciden en que el precio de las acciones subirá un 20.7%

Análisis de riesgos

Tiene un alto nivel de endeudamiento


Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Biopharma Innovations And Critical Growth Initiatives Propel Earnings And Margin Expansion

Key Takeaways Strategic initiatives focused on productivity and organic growth are expected to enhance operational efficiency and drive margin expansion. Successful biosimilar launches and market access efforts support sustained revenue growth and improved financial flexibility.
View narrative
€40.06
FV
16.8% undervalued intrinsic discount
2.62%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
4 days ago author updated this narrative
TO
Tokyo
Community Contributor

First comes the pain, then the money.

My main narrative for FRE: What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain: Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation under Mark Schneider the Spanish hospitals were acquired, this was a good deal: privat hospital runs well in Spain, because of their good reputation wealthy Latin Americans travel for medical treatments to Spain I focus also on: More equity than debt. Ratio is at 62% (debt/equity).
View narrative
€74.00
FV
55.0% undervalued intrinsic discount
24.16%
Revenue growth p.a.
3users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
5 months ago author updated this narrative

Competidores de Fresenius SE & Co. KGaA

Fresenius Medical Care

XTRA:FME

€12.4b

SYNLAB

HMSE:SYAB

€2.5b

Siemens Healthineers

XTRA:SHL

€55.6b

Labcorp Holdings

NYSE:LH

US$20.0b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Fresenius SE KGaA
Precios históricos de las acciones
Precio actual de la acción€33.31
Máximo en las últimas 52 semanas€36.24
Mínimo de 52 semanas€24.32
Beta1.04
1Cambio en 1 mes-1.62%
Variación en 3 meses1.40%
Cambio de 1 año19.22%
3Variación en 3 años-2.16%
Variación en 5 años-32.90%
Variación desde la OPV2,850.42%

Noticias y actualizaciones recientes

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19
Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Recent updates

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19
Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jul 15
We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

Jun 12
Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28
At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02
With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29
Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Mar 13
Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Feb 06
Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Jan 19
A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Jan 03
Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Nov 28
Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10
Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27
Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25
Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19
We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01
At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18
Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13
Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23
Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08
Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03
The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23
Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01
The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20
Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02
Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28
Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17
At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02
Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27
Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24
Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Rentabilidad de los accionistas

FREDE HealthcareMercado DE
7D-0.1%0.1%-0.02%
1Y19.2%17.2%8.2%

Rentabilidad vs. Industria: FRE superó a la industria German Healthcare, que obtuvo un rendimiento del 17.2% el año pasado.

Rentabilidad vs. Mercado: FRE superó al mercado German, que obtuvo un rendimiento del 8.2% el año pasado.

Volatilidad de los precios

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement2.7%
Healthcare Industry Average Movement4.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.3%

Precio estable de las acciones: FRE no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de FRE (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
1912177,091Michael Senwww.fresenius.com

Fresenius SE & Co. KGaA, una empresa de asistencia sanitaria, ofrece productos y servicios para pacientes con enfermedades crónicas. Opera a través de cuatro segmentos: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios y Fresenius Vamed. El segmento Fresenius Medical Care ofrece productos y servicios para pacientes con insuficiencia renal crónica.

Resumen de fundamentos de Fresenius SE & Co. KGaA

¿Cómo se comparan los beneficios e ingresos de Fresenius SE KGaA con su capitalización de mercado?
Estadísticas fundamentales de FRE
Capitalización bursátil€18.76b
Beneficios(TTM)-€479.00m
Ingresos (TTM)€22.81b

0.8x

Ratio precio-ventas (PS)

-39.2x

Ratio precio-beneficio (PE)

¿Está FRE sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de FRE
Ingresos€22.81b
Coste de los ingresos€17.48b
Beneficio bruto€5.33b
Otros gastos€5.81b
Beneficios-€479.00m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-0.85
Margen bruto23.37%
Margen de beneficio neto-2.10%
Ratio deuda/patrimonio60.9%

¿Cómo se ha desempeñado FRE a largo plazo?

Ver rendimiento histórico y comparativa